http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 08:13:44 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/VolitionRx+files+patent+for+Ebola+test+using+Nu.Q+technology/26595812.html <p>VolitionRx Limited (NYSE AMERICAN: VNRX) filed a patent application covering the use of its Nu.Q technology for triaging and monitoring patients suspected of having Ebola virus, the company announced.</p><p>The patent application covers the company's Nu.Q NETs test, which quantifies circulating nucleosomes and Neutrophil Extracellular Traps as indicators of hyper-inflammation that can lead to septic shock and early mortality, according to the press release.</p><p>"This filing yet again shows the breadth of utility of our technology: it claims the potential use of Volition's existing Nu.Q NETs test for Ebola," said Dr. Jake Micallef, Chief Scientific Officer at VolitionRx.</p><p>The company's existing product portfolio http://www.streetinsider.com/Corporate+News/VolitionRx+files+patent+for+Ebola+test+using+Nu.Q+technology/26595812.html Wed, 03 Jun 2026 08:13:44 -0400 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/Press+Releases/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html <div class="xn-content"> <p class="prntac"><b><i>Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients <span value="ACORN:1756895745" idsrc="xmltag.org" >who</span> are suspected of having contracted the Ebola virus.</p> <p><b>Dr. <person>Jake Micallef</person></b>, Chief Scientific Officer, Volition commented:</p><p>"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing http://www.streetinsider.com/PRNewswire/VolitionRx+Files+New+Patent+Protecting+its+Nu.Q%C2%AE+NETs+Test+for+Ebola+Triage+and+Treatment+Monitoring/26595801.html Wed, 03 Jun 2026 08:12:00 -0400 A.17568957 O.04889877 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++VOLITIONRX+LTD++++++++++++For%3A+Jul+17/26592039.html si-local-file:///var/storage/secattach/20260602/26592039.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++VOLITIONRX+LTD++++++++++++For%3A+Jul+17/26592039.html Tue, 02 Jun 2026 16:22:00 -0400 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++VOLITIONRX+LTD++++++++++++For%3A+Jul+17/26592039.html si-local-file:///var/storage/secattach/20260602/26592039.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++VOLITIONRX+LTD++++++++++++For%3A+Jul+17/26592039.html Tue, 02 Jun 2026 16:22:00 -0400 O.06705185 VNRX http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Hold+Rating+on+VolitionRX+%28VNRX%29/26588283.html <p>Benchmark analyst Bruce Jackson reiterated a Hold rating on VolitionRX (NYSE: VNRX).</p><p>The analyst commented, "VolitionRx continues to practice tight expense control and plans to reduce its burn further in 2026 as it awaits the completion of possible milestones, product launches and potential licensing deals, which could provide enough cash to offset its roughly $5 million a quarter in operating cash requirements. The company ended the quarter with $3.1 million in cash. Publication of the study results for a feline cancer test, which has been submitted for publication, would trigger a $5 million milestone payment sometime later this year. After receiving http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Hold+Rating+on+VolitionRX+%28VNRX%29/26588283.html Tue, 02 Jun 2026 08:42:50 -0400 VNRX http://www.streetinsider.com/Corporate+News/VolitionRx+reports+300%25+Q1+revenue+growth%2C+submits+feline+cancer+test/26553986.html <p>VolitionRx Limited (NYSE AMERICAN: VNRX) reported $1 million in first-quarter 2026 revenue, marking a 300% increase from the prior year period, according to a company statement.</p><p>The Henderson, Nevada-based epigenetics company submitted a clinical manuscript for its Nu.Q Vet cancer test in cats, which could trigger a $5 million milestone payment upon publication. The test demonstrated 86% detection of feline lymphomas with 97% specificity in clinical studies.</p><p>VolitionRx said it has active licensing discussions with more than a dozen diagnostic and liquid biopsy companies. The company submitted a paper for peer review on its Capture-Seq platform, which detected over 95% of Stage http://www.streetinsider.com/Corporate+News/VolitionRx+reports+300%25+Q1+revenue+growth%2C+submits+feline+cancer+test/26553986.html Wed, 27 May 2026 08:17:51 -0400 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html <div class="xn-content"> <p><b><i>Update Highlights 300% Q1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p title="Chief Executive Officer, Cameron Reynolds provides a commercial update."><iframe width="560" height="315" src="https://www.youtube.com/embed/1IDfE7zKHG4" http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26553977.html Wed, 27 May 2026 08:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX